<DOC>
	<DOCNO>NCT00296504</DOCNO>
	<brief_summary>GW433908 ( fosamprenavir ; FPV ) pro-drug amprenavir ( APV ) water soluble formulate tablet reduce pill burden ( four 700mg tablet FPV versus sixteen 150mg capsule daily APV . This study design provide additional information long term safety tolerability FPV contain regimen subject receive FPV previous GlaxoSmithKline study .</brief_summary>
	<brief_title>A Study To Assess GW433908 ( Fosamprenavir ) Containing Regimens In HIV-1 Infected Subjects</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Male nonpregnant/nonlactating female &gt; /=13 year age ( &gt; /= 18 year age accord local requirement ) . Received fosamprenavir prior participation APV20001 , APV30002 , APV30003 PRO30017 participate APV30001 study deem appropriate project team . Permanent discontinuation GW433908 previous study due intolerance . An active CDC Class C Event . Any condition , opinion investigator , would preclude subject participation .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>antiretroviral therapy naive subject</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>HIV-1</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>pro-drug</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>LEXIVA</keyword>
	<keyword>AGENERASE</keyword>
	<keyword>GW433908</keyword>
	<keyword>amprenavir</keyword>
</DOC>